These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 19491903

  • 1. Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours.
    Hussein D, Holt SV, Brookes KE, Klymenko T, Adamski JK, Hogg A, Estlin EJ, Ward T, Dive C, Makin GW.
    Br J Cancer; 2009 Jul 07; 101(1):55-63. PubMed ID: 19491903
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
    Loadman PM, Phillips RM, Lim LE, Bibby MC.
    Biochem Pharmacol; 2000 Apr 01; 59(7):831-7. PubMed ID: 10718341
    [Abstract] [Full Text] [Related]

  • 3. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
    Dehn DL, Winski SL, Ross D.
    Clin Cancer Res; 2004 May 01; 10(9):3147-55. PubMed ID: 15131056
    [Abstract] [Full Text] [Related]

  • 4. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
    Ward TH, Danson S, McGown AT, Ranson M, Coe NA, Jayson GC, Cummings J, Hargreaves RH, Butler J.
    Clin Cancer Res; 2005 Apr 01; 11(7):2695-701. PubMed ID: 15814651
    [Abstract] [Full Text] [Related]

  • 5. Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
    Kim JY, West CM, Valentine H, Ward TH, Patterson AV, Stratford IJ, Roberts SA, Hendry JH.
    Radiother Oncol; 2004 Mar 01; 70(3):311-7. PubMed ID: 15064018
    [Abstract] [Full Text] [Related]

  • 6. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
    Park MT, Song MJ, Oh ET, Lee H, Choi BH, Jeong SY, Choi EK, Park HJ.
    Br J Pharmacol; 2011 Jun 01; 163(3):567-85. PubMed ID: 21250978
    [Abstract] [Full Text] [Related]

  • 7. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
    Kim JY, Patterson AV, Stratford IJ, Hendry JH.
    Anticancer Drugs; 2004 Jan 01; 15(1):71-7. PubMed ID: 15090746
    [Abstract] [Full Text] [Related]

  • 8. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
    Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D.
    Mol Pharmacol; 2008 Dec 01; 74(6):1657-65. PubMed ID: 18794327
    [Abstract] [Full Text] [Related]

  • 9. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
    Digby T, Leith MK, Thliveris JA, Begleiter A.
    Cancer Chemother Pharmacol; 2005 Sep 01; 56(3):307-16. PubMed ID: 15877230
    [Abstract] [Full Text] [Related]

  • 10. Activity profile of the novel aziridinylbenzoquinones MeDZQ and RH1 in human tumour xenografts.
    Cummings J, Ritchie A, Butler J, Ward TH, Langdon S.
    Anticancer Res; 2003 Sep 01; 23(5A):3979-83. PubMed ID: 14666706
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
    Scotlandi K, Perdichizzi S, Manara MC, Serra M, Benini S, Cerisano V, Strammiello R, Mercuri M, Reverter-Branchat G, Faircloth G, D'Incalci M, Picci P.
    Clin Cancer Res; 2002 Dec 01; 8(12):3893-903. PubMed ID: 12473605
    [Abstract] [Full Text] [Related]

  • 12. DT-diaphorase: a target for new anticancer drugs.
    Danson S, Ward TH, Butler J, Ranson M.
    Cancer Treat Rev; 2004 Aug 01; 30(5):437-49. PubMed ID: 15245776
    [Abstract] [Full Text] [Related]

  • 13. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
    Winski SL, Hargreaves RH, Butler J, Ross D.
    Clin Cancer Res; 1998 Dec 01; 4(12):3083-8. PubMed ID: 9865924
    [Abstract] [Full Text] [Related]

  • 14. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
    Nemeikaite-Ceniene A, Dringeliene A, Sarlauskas J, Cenas N.
    Acta Biochim Pol; 2005 Dec 01; 52(4):937-41. PubMed ID: 15940348
    [Abstract] [Full Text] [Related]

  • 15. Structure-activity study with bioreductive benzoquinone alkylating agents: effects on DT-diaphorase-mediated DNA crosslink and strand break formation in relation to mechanisms of cytotoxicity.
    Fourie J, Guziec F, Guziec L, Monterrosa C, Fiterman DJ, Begleiter A.
    Cancer Chemother Pharmacol; 2004 Mar 01; 53(3):191-203. PubMed ID: 14614574
    [Abstract] [Full Text] [Related]

  • 16. Down-regulation of XIAP by AEG35156 in paediatric tumour cells induces apoptosis and sensitises cells to cytotoxic agents.
    Holt SV, Brookes KE, Dive C, Makin GW.
    Oncol Rep; 2011 Apr 01; 25(4):1177-81. PubMed ID: 21286665
    [Abstract] [Full Text] [Related]

  • 17. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski SL, Swann E, Hargreaves RH, Dehn DL, Butler J, Moody CJ, Ross D.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1509-16. PubMed ID: 11377380
    [Abstract] [Full Text] [Related]

  • 18. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
    Hasinoff BB, Begleiter A.
    Free Radic Res; 2006 Sep 15; 40(9):974-8. PubMed ID: 17015278
    [Abstract] [Full Text] [Related]

  • 19. Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1.
    Danson SJ, Johnson P, Ward TH, Dawson M, Denneny O, Dickinson G, Aarons L, Watson A, Jowle D, Cummings J, Robson L, Halbert G, Dive C, Ranson M.
    Ann Oncol; 2011 Jul 15; 22(7):1653-1660. PubMed ID: 21378203
    [Abstract] [Full Text] [Related]

  • 20. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
    Dehn DL, Inayat-Hussain SH, Ross D.
    J Pharmacol Exp Ther; 2005 May 15; 313(2):771-9. PubMed ID: 15665137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.